MMJ Phytotech eyes Australia
Published 13-OCT-2015 10:44 A.M.
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
There are signs the Victorian government’s move to legalise medical cannabis could open up a new industry, with pharmaceutical player MMJ Phytotech (ASX:MMJ) saying it would now look at the Australian market on the back of a regulatory win.
The Victorian government, led by Daniel Andrews, recently announced that it would introduce legislation before the year was out which would allow locally manufactured cannabis products to be supplied to those with serious medical conditions.
These can include illnesses such as cancer, multiple sclerosis, HIV/AIDS, epilepsy and chronic pain.
“I’ve seen first-hand how medicinal cannabis can change people’s lives. This landmark reform means Victorian families will no longer have to decide between breaking the law and watching their child suffer,” Andrews said at the time, backing up sentiment from health minister Jill Hennessy.
“Victoria is leading the way on legalising medicinal cannabis because we know the difference it can make to a patient’s quality of life, and because we know the evidence is growing in support of it as a treatment option in exceptional circumstances,” she said.
The move from the government came from a review done by the Victorian Law Reform Commission, which found that the use of locally manufactured cannabis products to treat the ill should be allowed in “exceptional circumstances”.
It also recommended that growers and providers of medicinal cannabis products should be licensed by the state.
MMJ Phytotech, which has started sales of its first cannabinoid pill overseas has now flagged its interest in working in Australia, saying its experience would give it a natural advantage over start-ups.
“Our expertise in the medical cannabis market positions us at the forefront of the embryonic industry in Australia,” chief executive Andreas Gedeon said.
“Through our investigations into the opportunity in the market we hope to one day become one of the leading providers of safe and secure medical cannabis in the state of Victoria, Australia.”
On the federal front, there is a private members bill currently being considered by the Senate which would allow for the manufacture and sale of medical cannabis products on a wider scale.
It was sponsored by representatives from the Greens, Liberals, Labor, and crossbencher David Leyonhjelm.
Meanwhile, it told shareholders that it would be able to produce from its Duncan facility in Canada by the first quarter of next year.
Farm to Pharma
MMJ is positioning itself as a ‘farm to pharma’ player in the medical pharmaceutical industry, aiming to have a presence in the growth, extraction, and manufacture of cannabidoil and tetrahydrocannabinol from cannabis plants.
Its Duncan facility in Canada comes under its United Greeneries offshoot, and is the ‘farm’ portion of the strategy.
Today it told investors that the Canadian government had completed a vita pre-inspection upgrade of the facility, and was now just awaiting the final check from the government.
When operational, the Duncan facility is slated to produce 700kg of medical cannabis.
It also has a second project in the works in Canada, which could bring production up to 12,000kg per year.
United Greeneries is fully integrated with a state-of-the-art biochemical quality testing and analytics laboratory at its disposal.
This is vital, as while it’s a requirement under Canadian law, not a lot of growers have this up their sleeve.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.